Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art

Pund, Swati; Joshi, Amita

doi:10.1016/b978-0-323-52727-9.00023-6

Cited by 35 publications

(32 citation statements)

References 345 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polymeric nanoparticles used as nanocarriers involve matrix architectures, most commonly in the form of nanocapsules and nanospheres [28,29]. The most widely used polymers for manufacturing these nanocarriers are biocompatible and biodegradable and of synthetic origin, such as polylactic acid, polyglycolic acid, polylactide-co-polyglycolic acid, poly(ε-caprolactone), and polymethyl methacrylate, and of natural origin, such as chitosan, alginate, gelatin, and albumin [28,30]. The pharmacokinetics of the encapsulated agents is mainly influenced by the structure of the polymer and the entrapping method [31].…”

Section: Nanocarriers For Brain Targetingmentioning

confidence: 99%

“…Solid-lipid nanoparticles are the new generation of colloidal nanocarriers consisting of surfactant-stabilized triglycerides, monoglycerides, hard fats, complex glyceride mixtures, or waxes, that are solid at both room and body temperatures [28,33,34]. Their structure usually involves a hydrophobic solid matrix core in which phospholipids are embedded through the hydrophobic tail regions.…”

Section: Nanocarriers For Brain Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

The field of neuronanomedicine has recently emerged as the bridge between neurological sciences and nanotechnology. The possibilities of this novel perspective are promising for the diagnosis and treatment strategies of severe central nervous system disorders. Therefore, the development of nano-vehicles capable of permeating the blood–brain barrier (BBB) and reaching the brain parenchyma may lead to breakthrough therapies that could improve life expectancy and quality of the patients diagnosed with brain disorders. The aim of this review is to summarize the recently developed organic, inorganic, and biological nanocarriers that could be used for the delivery of imaging and therapeutic agents to the brain, as well as the latest studies on the use of nanomaterials in brain cancer, neurodegenerative diseases, and stroke. Additionally, the main challenges and limitations associated with the use of these nanocarriers are briefly presented.

show abstract

Section: Nanocarriers For Brain Targetingmentioning

confidence: 99%

Section: Nanocarriers For Brain Targetingmentioning

confidence: 99%

Neuronanomedicine: An Up-to-Date Overview

et al. 2019

View full text Add to dashboard Cite

show abstract

“…-Despite significant advances in understanding cell biology, etiology, the patho physio logy of parasitic infections and parasitic genome, there is currently no available vaccine for trypanosomiasis. It is due to the fact that parasitic infections do not stimulate immune system (73). In the absence of an available vaccine for trypanosomiases, antiparasitic chemotherapy remains the only option for both clinical management and control of these diseases (59,73).…”

Section: Antitrypanosomal Activitymentioning

confidence: 99%

“…It is due to the fact that parasitic infections do not stimulate immune system (73). In the absence of an available vaccine for trypanosomiases, antiparasitic chemotherapy remains the only option for both clinical management and control of these diseases (59,73). Effective drugs should be able to treat both stages of the disease or at least one of them.…”

Section: Antitrypanosomal Activitymentioning

confidence: 99%

2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses

Şerban

2020

Acta Pharmaceutica

View full text Add to dashboard Cite

Parasitic diseases are a serious public health problem affecting hundreds of millions of people worldwide. African trypanosomiasis, American trypanosomiasis, leishmaniasis, malaria and toxoplasmosis are the main parasitic infections caused by protozoan parasites with over one million deaths each year. Due to old medications and drug resistance worldwide, there is an urgent need for new antiparasitic drugs. 1,3,4-Thiadiazoles have been widely studied for medical applications. The chemical, physical and pharmacokinetic properties recommend 1,3,4-thiadiazole ring as a target in drug development. Many scientific papers report the antiparasitic potential of 2-amino-1,3,4-thiadiazoles. This review presents synthetic 2-amino-1,3,4-thiadiazoles exhibiting antitrypanosomal, antimalarial and antitoxoplasmal activities. Although there are insufficient results to state the quality of 2-amino-1,3,4-thiadiazoles as a new class of antiparasitic agents, many reported derivatives can be considered as lead compounds for drug synthesis and a promise for the future treatment of parasitosis and provide a valid strategy for the development of potent antiparasitic drugs.

show abstract

“…Moreover, the progress has been uneven in many parts of the world as millions of people lack access to life‐saving prevention measures and treatment; growing resistance to drugs, severe adverse effects, unfavorable toxicity profiles, and complicated drug administration procedures threaten to reverse the gains (WHO, ). It is noteworthy to mention that, for some of these maladies such as Chagas disease, currently used drugs are also not necessarily effective upon all parasite life cycle stages and/or stages of the disease (Pund & Joshi, ).…”

Section: Introductionmentioning

confidence: 99%

Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue

Boniface

Ferreira

2019

Phytotherapy Research

View full text Add to dashboard Cite

Endemic in 149 tropical and subtropical countries, neglected tropical diseases (NTDs) affect more than 1 billion people annually with over 500,000 deaths. Among the NTDs, some of the most severe consist of leishmaniasis, Chagas disease, and dengue. The impact of the combined NTDs closely rivals that of malaria. According to the World Health Organization, 216 million cases of malaria were reported in 2016 with 445,000 deaths. Current treatment options are associated with various limitations including widespread drug resistance, severe adverse effects, lengthy treatment duration, unfavorable toxicity profiles, and complicated drug administration procedures. Flavonoids are a class of compounds that has been the subject of considerable scientific interest. New developments of flavonoids have made promising advances for the potential treatment of malaria, leishmaniasis, Chagas disease, and dengue, with less toxicity, high efficacy, and improved bioavailability. This review summarizes the current standings of the use of flavonoids to treat malaria and neglected diseases such as leishmaniasis, Chagas disease, and dengue. Natural and synthetic flavonoids are leading compounds that can be used for developing antiprotozoal and antiviral agents. However, detailed studies on toxicity, pharmacokinetics, and mechanisms of action of these compounds are required to confirm the in vitro pharmacological claims of flavonoids for pharmaceutical applications. Highlights In the current review, we have tried to compile recent discoveries on natural and synthetic flavonoids as well as their implication in the treatment of malaria, leishmaniasis, Chagas disease, and dengue. A total of 373 (220 natural and 153 synthetic) flavonoids have been evaluated for antimalarial, antileishmanial, antichagasic, and antidengue activities. Most of these flavonoids showed promising results against the above diseases. Reports on molecular modeling of flavonoid compounds to the disease target indicated encouraging results. Flavonoids can be prospected as potential leads for drug development; however, more rigorously designed studies on toxicity and pharmacokinetics, as well as the quantitative structure–activity relationship studies of these compounds, need to be addressed.

show abstract

Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art

Cited by 35 publications

References 345 publications

Neuronanomedicine: An Up-to-Date Overview

Neuronanomedicine: An Up-to-Date Overview

2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses

Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue

Contact Info

Product

Resources

About